Loading
Independent radiologists who re-read every scan in a trial the same way, so response rates mean the same thing across hospitals.
Blinded independent central review (BICR) applies RECIST, iRECIST, Lugano, or PCWG3 criteria consistently across sites and is expected by regulators for PFS and ORR endpoints. Vendors: Calyx (formerly Parexel Informatics), ICON Medical Imaging, Clario (Bioclinica + ERT), Median Technologies, WCG Imaging, and Radiology Partners' research arm. AI-assisted lesion tracking and quantitative imaging biomarkers are entering the workflow.
De-identified DICOM images uploaded to a central platform; two readers plus adjudicator score per protocol charter; discrepancy rates and read variability are tracked.
Query for this technology: (TITLE:"Imaging core labs and central review" OR ABSTRACT:"Imaging core labs and central review") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Imaging core labs and central review, not a curated reading list.
Shares Clario, Contract research organisations (CROs) and the tag supporting.
Shares Contract research organisations (CROs) and the tag supporting.
Shares Contract research organisations (CROs) and the tag supporting.
Shares Contract research organisations (CROs) and the tag supporting.
Shares Contract research organisations (CROs) and the tag supporting.
Shares Contract research organisations (CROs) and the tag supporting.
Shares PET/CT, CT (computed tomography) and the tag supporting.
Shares PET/CT, CT (computed tomography) and the tag supporting.